BPC-157
Body Protection Compound 15-mer
Overview
BPC-157 (Body Protection Compound) is a 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a protective protein originally isolated from human gastric juice. The sequence is unusually proline-rich, which gives the molecule remarkable resistance to gastric and serum protease degradation, a property that has driven its broad use across tissue-repair research models including tendon-ligament healing, gastrointestinal mucosal protection, vascular endothelial repair, and post-injury bone metabolism studies. BPC-157 is on the July 2026 FDA PCAC agenda for 503A bulks-list consideration; see our [503A vs 503B compounding pathway guide](/lab-notes/503a-vs-503b-compounding-pharmacy-peptides) and [BPC-157 sourcing guide](/lab-notes/bpc-157-sourcing-guide-compounding-pharmacies) for the regulatory and procurement context. Lyochem supplies BPC-157 acetate as a lyophilized powder at ≥99.0% HPLC purity. Because BPC-157's relatively short sequence is reliable in solid-phase synthesis but the closely-eluting truncation by-products require careful purification, every batch ships with peak-integration HPLC plus ESI mass spec confirming the molecular weight within 0.5 Da of the theoretical 1419.55 g/mol. Sequence verification by LC-MS/MS (full b- and y-ion ladder) is available on request and is the recommended first-time qualification test for any new BPC-157 supplier, mass alone confirms identity, but tandem MS directly demonstrates the synthesized sequence matches the labelled sequence. BPC-157 is also a standard component of the Wolverine Blend (BPC-157 + TB-500) and the GLOW Blend custom formulations. For the side-by-side mechanism comparison with TB-500, see our [BPC-157 vs TB-500 article](/lab-notes/bpc-157-vs-tb-500-side-by-side).
Who buys this, and why
Repair peptides — BPC-157, TB-500, B7-33, PEG-MGF — ship primarily to research labs studying tissue-repair, gastrointestinal-mucosa, tendon-ligament, and vascular-endothelial models. The synthesis itself is reliable, but analytical confirmation is where suppliers differ: buyers qualifying a new source should request sequence verification by tandem MS on the first lot and compare against the labelled sequence directly.
Primary buyer fit: research laboratories that have validated this peptide into their workflow and academic and contract research laboratories.
Specifications
- CAS
- 137525-51-0
- Molecular Formula
- C62H98N16O22
- Molecular Weight
- 1419.55 g/mol
- Sequence
- GEPPPGKPADDAGLV
- Appearance
- White lyophilized powder
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 2 mg, 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 7–14 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (acetate vs TFA)
- Solubility / reconstitution guidance
- Stability data at −20 °C on request
Regulatory note
Currently under FDA PCAC review (July 2026) for inclusion on the 503A bulks list. Supplied for research and commercial use in compliance with the buyer's local regulations.
Frequently asked questions
What is the sequence of BPC-157, and why is it so stable?▾
BPC-157 is a 15-amino-acid peptide with sequence GEPPPGKPADDAGLV, note the four prolines in the first eight residues (PPPGKP). Proline kinks the peptide backbone in a way that resists protease access, which is why BPC-157 maintains structural integrity in gastric and serum environments where most short peptides degrade quickly. This stability is the molecular basis for the oral-route research interest in BPC-157, distinguishing it from peptides like TB-500 that are usable only via injectable routes.
Is BPC-157 approved by the FDA, and what's the regulatory trajectory?▾
BPC-157 is not an approved finished drug in any major jurisdiction. As of the current cycle, it is under FDA Pharmacy Compounding Advisory Committee (PCAC) review for inclusion on the 503A bulks list, with the proposed indication of ulcerative colitis (July 2026 meeting agenda). If the FDA accepts PCAC's recommendation, compounding pharmacies could use BPC-157 for patient-specific compounding under 503A. Until then, it is sold as a bulk active for research and for commercial use in jurisdictions where local regulations permit.
What's the difference between BPC-157 free base and BPC-157 acetate, and which does Lyochem ship?▾
BPC-157 acetate is the more commonly produced salt form and is what Lyochem ships by default. Free base BPC-157 is the unsalted molecule and is occasionally requested for formulators who want to control the final counter-ion in their downstream product. The HPLC peak retention time differs slightly between the two forms, acetate elutes earlier under typical reverse-phase conditions, but the biological activity per mass of peptide is equivalent. Specify free base vs. acetate at quote stage if it matters for your downstream work.
Can BPC-157 be co-formulated with TB-500 in a single vial?▾
Yes, the BPC-157 + TB-500 combination is one of the most-requested blends in our catalog, sold as the Wolverine Blend SKU. Co-lyophilization in a single vial is preferred over the buyer mixing the two in solution because it preserves potency better and the analytical packet certifies the actual ratio in the released vial. Standard Wolverine Blend ratios are 5+5 mg in a 10 mg vial; custom ratios (10+5, 10+10, 5+10) are available via OEM service. GHK-Cu can also be added to the blend (the GLOW Blend SKU) for combined repair-plus-cosmetic-tissue research.
Related peptides